Alseres Pharmaceuticals Inc De (ALSE) SEC Filing 8-K Material Event for the period ending Thursday, December 12, 2013

Alseres Pharmaceuticals Inc De

CIK: 94784 Ticker: ALSE

View differences made from one to another to evaluate Alseres Pharmaceuticals Inc De's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alseres Pharmaceuticals Inc De.


Assess how Alseres Pharmaceuticals Inc De's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Alseres Pharmaceuticals Inc De's Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ALSE
CIK: 94784
Form Type: 8-K Corporate News
Accession Number: 0001193125-13-475540
Submitted to the SEC: Tue Dec 17 2013 11:14:32 AM EST
Accepted by the SEC: Tue Dec 17 2013
Period: Thursday, December 12, 2013
Industry: Pharmaceutical Preparations
  1. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: